"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Descriptor ID |
D000970
|
MeSH Number(s) |
D27.505.954.248
|
Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 12 | 2 | 14 |
1995 | 5 | 2 | 7 |
1996 | 13 | 2 | 15 |
1997 | 8 | 1 | 9 |
1998 | 23 | 7 | 30 |
1999 | 9 | 9 | 18 |
2000 | 17 | 7 | 24 |
2001 | 25 | 6 | 31 |
2002 | 37 | 12 | 49 |
2003 | 32 | 12 | 44 |
2004 | 38 | 13 | 51 |
2005 | 34 | 20 | 54 |
2006 | 38 | 21 | 59 |
2007 | 49 | 18 | 67 |
2008 | 35 | 18 | 53 |
2009 | 45 | 25 | 70 |
2010 | 58 | 28 | 86 |
2011 | 64 | 19 | 83 |
2012 | 55 | 26 | 81 |
2013 | 54 | 24 | 78 |
2014 | 70 | 23 | 93 |
2015 | 78 | 32 | 110 |
2016 | 60 | 30 | 90 |
2017 | 54 | 25 | 79 |
2018 | 43 | 25 | 68 |
2019 | 44 | 23 | 67 |
2020 | 33 | 17 | 50 |
2021 | 42 | 14 | 56 |
2022 | 19 | 2 | 21 |
2023 | 38 | 0 | 38 |
2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
The potent paracrine effect of umbilical cord mesenchymal stem cells mediates mitochondrial quality control to restore chemotherapy-induced damage in ovarian granulosa cells. Biomed Pharmacother. 2024 Mar; 172:116263.
-
Special designations and the US Food and Drug Administration's "dual mandate". J Natl Cancer Inst. 2024 Feb 08; 116(2):177-179.
-
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb; 8:e2300513.
-
Discordant Effects of Polyamine Depletion by DENSpm and DFMO on ß-cell Cytokine Stress and Diabetes Outcomes in Mice. Endocrinology. 2024 Jan 16; 165(3).
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
-
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clin Cancer Res. 2023 12 01; 29(23):4751-4759.
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
-
Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study. J Patient Rep Outcomes. 2023 Nov 10; 7(1):113.
-
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource. Mol Cancer Ther. 2023 Nov 01; 22(11):1270-1279.
-
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors. Lung Cancer. 2023 12; 186:107417.